Open AccessReview: Recombinant human erythropoietin: novel strategies for neuroprotective/neuroregenerative treatment of multiple sclerosis
Author(s) -
Claudia Bartels,
Kira Späte,
Henning Krampe,
Hannelore Ehrenreich
Publication year - 2008
Publication title -
therapeutic advances in neurological disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.684
H-Index - 50
eISSN - 1756-2864
pISSN - 1756-2856
DOI - 10.1177/1756285608098422
Subject(s) - medicine , neuroprotection , erythropoietin , multiple sclerosis , experimental autoimmune encephalomyelitis , neuroscience , stroke (engine) , neuroplasticity , neurotrophic factors , glatiramer acetate , central nervous system , immunology , pharmacology , receptor , psychology , psychiatry , engineering , mechanical engineering
Treatment of multiple sclerosis (MS) is still unsatisfactory and essentially non-existing for the progressive course of the disease. Recombinant human erythropoietin (EPO) may be a promising neuroprotective/neuroregenerative treatment of MS. In the nervous system, EPO acts anti-apoptotic, antioxidative, anti-inflammatory, neurotrophic and plasticity-modulating. Beneficial effects have been shown in animal models of various neurological and psychiatric diseases, including different models of experimental autoimmune encephalomyelitis. EPO is also effective in human brain disease, as shown in double-blind placebo-controlled clinical studies on ischemic stroke and chronic schizophrenia. An exploratory study on chronic progressive MS yielded lasting improvement in motor and cognitive performance upon high-dose long-term EPO treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom